Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
We tested the antibacterial activity of ophthalmic 0.3% ciprofloxacin against that of 5.0% cefazolin and 1.36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively. Both corneas of New Zealand white rabbits were intrastromally injected with either S. aureus or P. aeruginosa. Twenty-four hours later, each eye was topically treated hourly for 24 hours. In the S. aureus model, the control group received Tears Naturale Free (Alcon Laboratories, Inc., Fort Worth, TX), the ciprofloxacin group received 0.3%, ciprofloxacin and the cefazolin group received 5.0% cefazolin. In the P. aeruginosa model, the control group received Tears Naturale Free, the ciprofloxacin group received 0.3% ciprofloxacin, and the tobramycin group received 1.36% tobramycin. One hour after the last eyedrops were administered, the rabbits were killed, and their corneas were processed for quantification of bacteria. For the S. aureus model, the mean (+/- SEM) colony forming units (CFU) of the control, 7.1 x 10(6) (+/- 4.0 x 10(6)); ciprofloxacin, 6.4 x 10(2) (+/- 1.6 x 10(2)); and cefazolin, 1.3 x 10(3) (+/- 1.8 x 10(2)) groups were different (F = 17.5; p = 0.001). The ciprofloxacin and cefazolin groups were not different from each other (p = 0.034). The mean (+/- SEM) CFU for the control group in the P. aeruginosa model was 2.8 x 10(8) (+/- 1.7 x 10(7)). All corneas in the ciprofloxacin and tobramycin groups were sterile.(ABSTRACT TRUNCATED AT 250 WORDS)
Lauffenburger
M D
MD
Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill 27599-7040.
Cohen
K L
KL
D000287:Administration, Topical; D000818:Animals; D002437:Cefazolin / Q000008:administration & dosage / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000627:therapeutic use; D015169:Colony Count, Microbial; D003315:Cornea / Q000187:drug effects / Q000382:microbiology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D015818:Eye Infections, Bacterial / Q000188:drug therapy*; D007634:Keratitis / Q000188:drug therapy* / Q000382:microbiology; D009883:Ophthalmic Solutions; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000302:isolation & purification; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D002939:Ciprofloxacin; D002437:Cefazolin; D014031:Tobramycin